Lund, Sweden, 12:00 pm CET, 29 May 2020 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During May, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased with 10,500,000 due to the directed share issue as communicated on 26 May 2020.
As of 31 May 2020, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 64,388,740 shares, of which 63,153,740 are ordinary shares with one vote per share and 1,235,000 are series C shares with one-tenth of a vote per share. The number of votes in the company amounts to 63,277,240 votes.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
+46 (0) 708 76 87 87
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2021. The company is based in Lund, Sweden, and the net sales amounted to SEK 155 million in 2019. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.
The information in the press release is such that BONESUPPORT HOLDING AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 12:00 pm CET on 29 May 2020.